A study evaluating the interpatient variability of plasma-posaconazole-concentrations in acute leukemia patients and allogeneic stem cell transplant recipients receiving Posaconazole oral suspension for primary antifungal prophylaxis.

Trial Profile

A study evaluating the interpatient variability of plasma-posaconazole-concentrations in acute leukemia patients and allogeneic stem cell transplant recipients receiving Posaconazole oral suspension for primary antifungal prophylaxis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Posaconazole (Primary) ; Allogeneic stem cell therapy
  • Indications Aspergillosis; Candidiasis; Chagas disease; Graft-versus-host disease; Leukaemia; Mycoses; Oropharyngeal candidiasis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 06 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top